Lexaria Bioscience Corp. (LEXX)
NASDAQ (CM) NASDAQ (CM) Primary 
Lexaria Bioscience's Phase 1b study starts patient dosing, says H.C. Wainwright
H.C. Wainwright reiterates a Buy rating and $10 price target on Lexaria Bioscience shares after the company announced that the Phase 1b 12-week chronic study in Australia has started patient dosing as planned. The GLP-1-H24-4 study includes four planed DehydraTECH formulation arms and one Rybelsus comparator control arm and is slated to enroll 20 20 overweight, obese, pre- or type 2 diabetic patients for each of arms 1-4 at seven clinical sites, with the DehydraTECH-tirzepatide Arm 5 to be added at a later date if supported by positive results from the separate ongoing study GLP-1- H24-3, the analyst tells investors in a research note. Positive results from this study could expand the application of the DehydraTECH delivery technology in the GLP-1 sector, the firm says.
Lexaria Forms New Scientific Advisory Board
North American drug delivery development experts added to help guide Lexaria's strategic plans KELOWNA, BC / ACCESSWIRE / December 18, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the creation of its new Scientific Advisory Board ("SAB") to assist in guiding Lexaria's rapid drug delivery platform technology and strategic development plans within the pharmaceutical industry. The SAB will initially be comprised of four people and the Chairman of the SAB will be Lexaria's President and Chief Scientific Officer, John Docherty.
Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience
Dr. Gibson joining Lexaria's new scientific advisor board KELOWNA, BC / ACCESSWIRE / December 17, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the appointment of Dr. Michael Gibson as its new Chief Medical Advisor. Dr. Gibson will collaborate directly with President John Docherty as Lexaria's patented DehydraTECH drug delivery platform continues to expand its applications in GLP-1 and hypertension.
Lexaria Appoints Michael Shankman as Chief Financial Officer
KELOWNA, BC / ACCESSWIRE / October 1, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of Michael Shankman, CPA, as Chief Financial Officer (CFO) effective immediately. As a member of the executive leadership team, Mr.
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3
First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral format KELOWNA, BC / ACCESSWIRE / September 27, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that approval has been received from an independent review board, for human pilot study #3 (the "Study"), investigating a DehydraTECH-processed version of the dual action GLP-1 (glucagon-like peptide) + GIP (glucose-dependent insulinotropic peptide) tirzepatide in an oral dose format. Subject recruitment will begin shortly and the Company will announce as soon as the first dosing has begun, currently expected in late October.
Lexaria Releases Strategic Letter from the Outgoing CEO
KELOWNA, BC / ACCESSWIRE / September 5, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this letter from outgoing Chief Executive Officer ("CEO") Chris Bunka as a strategic update to all stakeholders. CEO LETTER TO STAKEHOLDERS It is with mixed emotions and a heavy heart that I write my final strategic letter to my Lexaria family.
Lexaria Welcomes Industry Veteran as New CEO
Outgoing CEO, Chris Bunka, to remain on as Chairman of the Board of Directors and Executive Strategic Advisor KELOWNA, BC / ACCESSWIRE / September 5, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that Chris Bunka, Chief Executive Officer ("CEO") of the Company, is stepping aside for the appointment of Richard Christopher as the new CEO, effective August 31, 2024. Mr. Christopher is a well-regarded industry veteran with more than three decades of experience in the medical device and pharmaceutical industries, with domestic and international experience in leadership, operations, acquisitions/licensing, business development, strategic planning and capital markets.
Lexaria Enters a Material Transfer Agreement for DehydraTECH Research
KELOWNA, BC / ACCESSWIRE / September 3, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has entered into a Material Transfer Agreement with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECHTM technology in a pre-clinical setting. Under the terms of the agreement, Lexaria is responsible for formulation and supply of certain DehydraTECH compositions.
Positive Results from Lexaria's Molecular Characterization Study
Monomeric form of GLP-1 drug preserved by DehydraTECH KELOWNA, BC / ACCESSWIRE / August 19, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces positive findings from its applied research program together with the National Research Council of Canada ("NRC") that evaluated important mode of action facets of DehydraTECH processed with the glucagon-peptide 1 ("GLP-1") drug, semaglutide. This highly technical work program examined the molecular properties of DehydraTECH-processed pure semaglutide in comparison to the commercially available semaglutide formulation Rybelsus® using simulated gastric fluid and thereby mimicking conditions in the human gut.
Lexaria Preparing For Strategic Growth
Strategic growth plan execution underway. KELOWNA, BC / ACCESSWIRE / July 16, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces plans for strategic growth.
Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy
Lexaria currently holding 46 granted patents worldwide KELOWNA, BC / ACCESSWIRE / July 8, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces three new patent awards. In the European Union, the Company has received a new granted patent in Lexaria's patent family #6: Transdermal and/or Dermal Delivery of Lipophilic Active Agents.
